Synthetic biology startup AbSci raises $65M to expand ‘Protein Printing’ tech

AbSci CEO and Founder Sean McClain. (AbSci Photo)

Vancouver, Wash.-based biotech company AbSci raised an additional $65 million to help grow its synthetic biology platform.

The company’s “Protein Printing” technology is used to discover and manufacture complex biological molecules such as antibodies and insulin.

The AbSci platform

This post was originally published on this site


Check out